Annual Report

Overview

The report highlights completion of the 24-month XSTEM knee osteoarthritis study, with continued safety, reduced knee pain, improved joint function and improved cartilage and bone structure. It also records a collaboration and license agreement with EQGen Biomedical for EQSTEM and other animal stem-cell products, and Targinta's collaboration with Memorial Sloan Kettering Cancer Center. Consolidated group net sales were 2,282 TSEK and the group loss for the period was -48,564 TSEK.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services